<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Escitalopram - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Escitalopram</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../../index.html">Home</a>
        <a class="btn small" href="../../index.html#/sickbay-meds">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Neuro / Psych</div>
      <h1>Escitalopram</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Escitalopram 10mg Tablets</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Major depressive disorder (MDD)</strong>
            <ul>
              <li>Initial: 10 mg PO once daily</li>
              <li>Maintenance: 10 mg PO once daily (may increase to 20 mg daily after minimum 1 week if needed and tolerated)</li>
            </ul>
          </li>
          <li><strong>Generalized anxiety disorder (GAD)</strong>
            <ul>
              <li>Initial: 10 mg PO once daily</li>
              <li>Maintenance: 10 mg PO once daily (may increase to 20 mg daily after minimum 1 week if needed)</li>
            </ul>
          </li>
          <li><strong>Other uses (off-label but common): panic disorder, social anxiety disorder, OCD</strong>
            <ul>
              <li>Dosing typically similar to above; follow specialist guidance when available</li>
            </ul>
          </li>
          <li><strong>Special populations</strong>
            <ul>
              <li>Older adults or hepatic impairment: consider starting at lower dose (5 mg daily if tablets can be split, or 10 mg every other day)</li>
              <li>Discontinuation: taper gradually (reduce by 50% every 1–2 weeks) to minimize withdrawal symptoms; do not stop abruptly</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Major depressive disorder</li>
          <li>Generalized anxiety disorder</li>
          <li>Off-label: panic disorder, social anxiety disorder, obsessive-compulsive disorder (OCD)</li>
          <li>Continuation of established therapy (most common use onboard)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Concurrent use of MAOIs (within 14 days of stopping MAOI; risk of serotonin syndrome)</li>
          <li>Hypersensitivity to escitalopram or citalopram</li>
          <li>Avoid in patients with known QT prolongation or concurrent QT-prolonging medications (escitalopram can prolong QTc, especially at higher doses)</li>
          <li>Caution in seizure disorders (may lower seizure threshold, though uncommon)</li>
          <li>Bleeding risk: SSRIs affect platelet function; caution with concurrent anticoagulants/antiplatelets or history of bleeding</li>
          <li>Activation of mania/hypomania in bipolar disorder (screen for bipolar history before initiating)</li>
          <li>Pregnancy/breastfeeding: discuss risks/benefits; SSRIs cross placenta and enter breast milk; follow current guidelines and specialist consultation</li>
          <li>Suicidality warning: monitor for worsening depression/suicidal ideation, especially in young adults <25 years during initial weeks of treatment</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Common: nausea, insomnia or somnolence, sexual dysfunction (decreased libido, delayed ejaculation), dry mouth, sweating</li>
          <li>Headache, dizziness, fatigue</li>
          <li>Weight changes (variable)</li>
          <li>Discontinuation syndrome if stopped abruptly: dizziness, paresthesias, irritability, nausea, "brain zaps" (taper to avoid)</li>
          <li>Serotonin syndrome (rare; risk with multiple serotonergic agents): agitation, confusion, tremor, hyperthermia, autonomic instability</li>
          <li>Hyponatremia (rare; more common in older adults or with diuretics)</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li>Take once daily, with or without food</li>
          <li>Morning or evening dosing—adjust based on individual response (if insomnia, take in morning; if sedation, take at bedtime)</li>
          <li>Counsel: therapeutic effect takes 2–4 weeks (sometimes up to 6–8 weeks for full benefit); do not expect immediate mood improvement</li>
          <li>Emphasize adherence: missing doses or stopping abruptly can worsen symptoms and cause withdrawal</li>
          <li>Avoid alcohol (may worsen sedation/impairment)</li>
          <li>Starting therapy onboard: generally avoid initiating new psychiatric medications in isolated maritime environments unless under specialist guidance; onboard use typically for continuation of established therapy</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Mood, anxiety symptoms, and functional status (weekly to monthly during adjustment phase)</li>
          <li>Suicidal ideation, especially in first 4–8 weeks or after dose changes (high-risk period)</li>
          <li>Adverse effects: nausea (usually improves after 1–2 weeks), sexual dysfunction, sleep disturbance, weight changes</li>
          <li>Activation/agitation or emergence of manic symptoms (stop and seek specialist consultation if occurs)</li>
          <li>If starting therapy: close follow-up by qualified provider (in-person or telehealth)</li>
          <li>For established therapy: ensure patient has adequate supply for voyage duration and plan for continuity of care</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li><strong>Most commonly used for continuation of established therapy</strong> rather than new starts; ensure patient has stable dose and adequate supply before departure</li>
          <li>Screen medication history during pre-voyage medical: confirm psychiatric medication use, stability, adherence, and refill needs</li>
          <li>If patient requests to start new antidepressant: coordinate with mental health provider ashore; avoid initiating in isolation without ongoing specialist support</li>
          <li>Monitor for adherence and side effects; check in regularly with patients on psychiatric medications (isolation, stress, and operational demands can impact mental health)</li>
          <li>If patient reports worsening depression, suicidal thoughts, or emergent mania: immediate telehealth consultation and consider evacuation if safety concerns</li>
          <li>Discontinuation: if patient wishes to stop, ensure gradual taper plan and close monitoring; coordinate with mental health provider</li>
          <li>Document doses, adherence, side effects, and mental status clearly for continuity of care at next port or if evacuation needed</li>
          <li>Ensure confidentiality and reduce stigma around mental health treatment</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (Cipralex / escitalopram): <a href="https://pdf.hres.ca/dpd_pm/00066619.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00066619.PDF</a></li>
          <li>DynaMed – Major Depressive Disorder overview: <a href="https://www.dynamed.com/condition/major-depressive-disorder-in-adults" target="_blank" rel="noopener">https://www.dynamed.com/condition/major-depressive-disorder-in-adults</a></li>
          <li>CANMAT Depression Guidelines: <a href="https://www.canmat.org/depression" target="_blank" rel="noopener">https://www.canmat.org/depression</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
